PHC & CCRM Collaborate Advance T-Cell Expansion
PHC and CCRM Partner to Develop T-Cell Expansion Processes for Enhanced Efficiency and Quality PHC Corporation has entered into a Master Collaboration Agreement with CCRM to develop primary T-cell expansion culture processes aimed at advancing cell and gene therapy (CGT)…
McKesson Reports Q3 Fiscal 2025 Results, Raises Full-Year EPS Guidance
McKesson Reports Q3 Fiscal 2025 Results, Raises Full-Year EPS Guidance McKesson Corporation (NYSE: MCK) announced its third-quarter results for the fiscal year 2025, showing strong growth across various segments. The company reported revenues of $95.3 billion for the quarter, a…
Teladoc Health to Acquire Catapult Health, Boosting Integrated Care
Teladoc Health to Acquire Catapult Health, Boosting Integrated Care Teladoc Health (NYSE: TDOC), a global leader in virtual care, has announced that it has entered into a definitive agreement to acquire Catapult Health, a provider of virtual preventive care services.…
Amplar Health to Provide Hotel-Based Transition Care in South Australia
Amplar Health to Provide Hotel-Based Transition Care in South Australia For the first time in South Australia, a city hotel will provide an innovative new location for hospital patients who no longer require acute care, allowing them to rest and…
Cencora Expands Drug Shortages Mitigation Program to Strengthen Supply Chain
Cencora Expands Drug Shortages Mitigation Program to Strengthen Supply Chain Cencora, a global leader in healthcare services, has significantly expanded its drug shortage mitigation initiative, the Sure Supply Program, to provide healthcare systems with a reliable and consistent supply of…
Results from AceLink’s Phase 2 AL01211 Study in Fabry Disease Presented at WORLD Symposium 2025
Results from AceLink’s Phase 2 AL01211 Study in Fabry Disease Presented at WORLD Symposium 2025 AceLink Therapeutics, a clinical-stage biotech firm focused on developing next-generation oral substrate reduction therapies (SRTs), presented interim results from its ongoing Phase 2 clinical study…
Agreement Terminated: Devonian Health Group Ends Distribution Deal
Agreement Terminated: Devonian Health Group Ends Distribution Deal Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical-stage company focused on developing innovative solutions for inflammatory diseases, announced that its pharmaceutical distribution division, Altius Health Group…
Crown Laboratories Finalizes Acquisition of Revance Therapeutics
Crown Laboratories Finalizes Acquisition of Revance Therapeutics Crown Laboratories, Inc., a global leader in innovative skincare solutions and a part of the Hildred Capital portfolio, has officially closed its acquisition of Revance Therapeutics, Inc., a biotechnology company focused on advancing…
Cyclo Therapeutics Presents Positive Phase 3 TransportNPC™ Data in Children Under 3
Cyclo Therapeutics Presents Positive Phase 3 TransportNPC™ Data in Children Under 3 Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical-stage biotechnology company focused on developing life-changing treatments for patients with rare and challenging diseases, today announced the presentation of data from…
Conference: Certis Oncology CEO Presents at 24th Annual Precision World Medicine
Conference: Certis Oncology CEO Presents at 24th Annual Precision World Medicine Certis Oncology Solutions, a leader in precision oncology and translational science, recently showcased its groundbreaking advancements in artificial intelligence (AI) and machine learning (AI/ML) at the 24th Annual Precision…
Transplant of Genetically Engineered Porcine Kidney Successfully Performed in Second Patient by eGenesis
Transplant of Genetically Engineered Porcine Kidney Successfully Performed in Second Patient by eGenesis eGenesis, a biotechnology firm focused on developing human-compatible engineered organs to help alleviate the global organ shortage, has announced the successful transplantation of a genetically engineered porcine…
Webinar on Ataxia-Telangiectasia Unmet Need Hosted by Quince Therapeutics
Webinar on Ataxia-Telangiectasia Unmet Need Hosted by Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company focused on advancing treatments for rare diseases, has announced that it will host an investor webinar today, Friday, February 7, 2025, at…